Penny Whiting

Datos Biográficos

ID7506583
NOMBREPenny Whiting
NOMBRESPenny
APELLIDOWhiting
FIRMAWHITING P
AFILIACIONESUniversity Hospitals Bristol NHS Foundation Trust
ORCID0000-0003-1138-5682
VERIFICADOSí
TOTAL DE OBRAS15
TOTAL DE CITAS0
TOTAL COMO AUTOR15
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2011
AÑO MÁS RECIENTE DE PUBLICACIÓN2022
ÍNDICE H0

  • Blood tests in primary care

    Open AccessJessica Watson, Penny Whiting et al.ARTICLEHealth Expectations2022

    OBJECTIVE: Blood tests are commonly used in primary care as a tool to aid diagnosis, and to offer reassurance and validation for patients. If doctors and patients do not have a shared understanding of the reasons for testing and the meaning of results, these aims may not be fulfilled. Shared decision-making is widely advocated; yet, most research focusses on treatment decisions rather than diagnostic decisions. The aim of this study was to explor…

  • A declaração PRISMA 2020

    Open AccessMatthew J Page, Joanne E McKenzie et al.ARTICLERevista Panamericana de Salud…2022

    A declaração dos Principais Itens para Relatar Revisões Sistemáticas e Meta-análises (PRISMA), publicada em 2009, foi desenvolvida para ajudar revisores sistemáticos a relatar de forma transparente por que a revisão foi feita, os métodos empregados e o que os autores encontraram. Na última década, os avanços na metodologia e terminologia de revisões sistemáticas exigiram a atualização da diretriz. A declaração PRISMA 2020 substitui a declaração d…

  • The PRISMA 2020 statement

    Open AccessMatthew J Page, Joanne E McKenzie et al.ARTICLEPLoS Medicine2021

  • The PRISMA 2020 statement

    Open AccessMatthew J Page, Joanne E McKenzie et al.ARTICLEJournal of Clinical Epidemiology2021

  • Declaración PRISMA 2020

    Open AccessMatthew J Page, Joanne E McKenzie et al.ARTICLERevista Española de Cardiología…2021

    La declaración PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses), publicada en 2009, se diseñó para ayudar a los autores de revisiones sistemáticas a documentar de manera transparente el porqué de la revisión, qué hicieron los autores y qué encontraron. Durante la última década, ha habido muchos avances en la metodología y terminología de las revisiones sistemáticas, lo que ha requerido una actualización de esta guía. La…

  • The PRISMA 2020 statement

    Open AccessMatthew J Page, Joanne E McKenzie et al.ARTICLEInternational Journal of Surgery2021

  • PRISMA 2020 explanation and elaboration

    Open AccessMatthew J Page, David Moher et al.ARTICLEBMJ2021

  • The PRISMA 2020 statement

    Open AccessMatthew J Page, Joanne E McKenzie et al.ARTICLEBMJ2021

  • The PRISMA 2020 statement

    Open AccessMatthew J Page, Joanne E McKenzie et al.ARTICLESystematic Reviews2021

  • The PRISMA 2020 statement

    Matthew J Page, Joanne Mckenzie et al.PREPRINT2020

    Background: The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did and what they found. Over the last decade, there have been many advances in systematic review methodology and terminology, which have necessitated an update to the guideline.Objectives: To develop the PRISMA 2020 statem…

  • RoB 2

    Open AccessJonathan Sterne, Jelena Savović et al.ARTICLEBMJ2019

    Assessment of risk of bias is regarded as an essential component of a systematic review on the effects of an intervention. The most commonly used tool for randomised trials is the Cochrane risk-of-bias tool. We updated the tool to respond to developments in understanding how bias arises in randomised trials, and to address user feedback on and limitations of the original tool.

  • Robis

    Open AccessPenny Whiting, Jelena Savović et al.ARTICLEJournal of Clinical Epidemiology2016

  • Robins-I

    Open AccessJonathan Sterne, Jonathan AC Sterne et al.ARTICLEBMJ2016

    Non-randomised studies of the effects of interventions are critical to many areas of healthcare evaluation, but their results may be biased. It is therefore important to understand and appraise their strengths and weaknesses. We developed ROBINS-I (“Risk Of Bias In Non-randomised Studies - of Interventions”), a new tool for evaluating risk of bias in estimates of the comparative effectiveness (harm or benefit) of interventions from studies that d…

  • Cannabinoids for Medical Use

    Penny Whiting, Penny F Whiting et al.ARTICLEJAMA2015

    IMPORTANCE: Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. OBJECTIVE: To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. DATA SOURCES: Twenty-eight databases from inception to April 2015. STUDY SELECTION: Randomized clinical trials of cannabinoids for the following indications: nausea and vomiting due to chemothe…

  • Quadas-2

    Open AccessPenny Whiting, Penny F Whiting et al.ARTICLEAnnals of Internal Medicine2011

    In 2003, the QUADAS tool for systematic reviews of diagnostic accuracy studies was developed. Experience, anecdotal reports, and feedback suggested areas for improvement; therefore, QUADAS-2 was developed. This tool comprises 4 domains: patient selection, index test, reference standard, and flow and timing. Each domain is assessed in terms of risk of bias, and the first 3 domains are also assessed in terms of concerns regarding applicability. Sig…